A pilot study to determine glycaemic variability in people with impaired glucose tolerance (prediabetes)

Abbott Diabetes Care Ltd0 sites43 target enrollmentMay 22, 2019

Overview

2020 Abstract results in https://doi.org/10.2337/db20-87-LB (added 01/07/2022) 2020 Abstract results in https://doi.org/10.1007/s00125-020-05221-5 (added 10/06/2024)

Registry

who.int

Start Date

May 22, 2019

End Date

August 31, 2019

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Abbott Diabetes Care Ltd

•1\. Aged 18 years or over.
•2\. Most recent HbA1c 5\.7\-6\.4% (39\-47 mmol/mol), recorded in medical notes in last 12 months.

•1\. Recorded diagnosis of diabetes.
•2\. Concomitant disease or condition that may compromise patient safety including and not limited to; cystic fibrosis, severe mental illness, a diagnosed or suspected eating disorder or any uncontrolled long term medical condition.
•3\. Has a pacemaker or any other neurostimulators.
•4\. Currently receiving dialysis treatment or planning to receive dialysis during the study.
•5\. Women who are pregnant, plan to become pregnant or become pregnant during the study.
•6\. Participating in another study of a glucose monitoring device or drug that could affect glucose measurements or management.
•7\. Known (or suspected) allergy to medical grade adhesives.
•8\. In the investigator’s opinion, unsuitable to participate due to any other cause/reason.